John Primrose, MD, ChB, FRCS, professor of medicine/surgery, University of Southampton, United Kingdom, discusses the impact of adjuvant capecitabine in patients with biliary tract cancer.
John Primrose, MD, ChB, FRCP
Advertisement
Articles by John Primrose, MD, ChB, FRCP
Advertisement
Latest Updated Articles
Dr. Primrose on Adjuvant Capecitabine For Biliary Tract CancerPublished: September 21st 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Prophylactic Dexamethasone Fails to Reduce Delayed Neurotoxicity Risk After CAR T-Cell Therapy in Myeloma
2
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
3
FDA Grants Fast Track Designation to Pelareorep Plus Bevacizumab/FOLFIRI in Second-Line KRAS-Mutant mCRC
4
TROP2-Directed ADCs Are Poised to Shake Up Frontline TNBC Management
5